Abyssinia Biologics

About:

Eradicating neurodegenerative diseases

Top Investors: Maine Technology Institute

Description:

Abyssinia is a preclinical stage biotech company focusing on soluble amyloid oligomers to treat, prevent and detect Alzheimer's disease.

Total Funding Amount:

$767000

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2017-06-01

Contact Email:

info(AT)aby-bio.com

Founders:

Frederic Godderis, Noah Ullman, Trebor R. Lawton

Number of Employees:

1-10

Last Funding Date:

2024-01-01

IPO Status:

Private

Industries: